Abstract
Obinutuzumab Short Duration Infusion Is Preferred By Healthcare Providers and Has Minimal Impact on Patient-Reported Symptoms Among Patients with Untreated, Advanced Follicular Lymphoma
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have